BD Resolves SEC Investigation – Dec 16, 2024
BD Updates Guidance, Expects Higher Revenue
BD, a global medical technology company, has updated its guidance for the fiscal year 2022 and expects revenue to be higher than previously anticipated. The company now projects revenue growth to be in the range of 11.5% to 12%, up from the earlier forecast of 9.5% to 10.5%.
This updated guidance reflects the strong performance of BD across all segments, including medication management solutions, surgical solutions, and patient safety solutions. The company’s focus on innovation and quality has driven growth and market penetration, leading to higher revenue projections for the fiscal year.
BD’s commitment to improving healthcare outcomes through its diverse portfolio of products and solutions has resonated well with customers and healthcare providers globally. The company’s dedication to environmental, social, and governance (ESG) principles has also contributed to its positive reputation and growth trajectory.
Investors are optimistic about BD’s performance and the revised revenue guidance, reflecting confidence in the company’s ability to deliver value and sustainable growth. The positive outlook for BD reaffirms its position as a leading player in the medical technology industry, driving innovation and positive change in healthcare worldwide.
